Almac Makes Further significant Co-Investment to Meet Japanese Client Demand for Humidity Controlled Blister Packaging
Almac has expanded its UK commercial packaging facility, with a significant investment, to provide a state-of-the-art humidity controlled blister packaging suite, complete with off-line “just in time” blister printing.
Meeting the requirements of two Japanese clients, the expansion included extensive suite modifications for processing humidity sensitive drug products; installation of a new Noack 623 blister line, a custom designed desiccant feeder and an off-line Hapa Blister-Jet printer.
The Noack blister line provides enhanced flexibility for processing larger blister sizes and innovative multi-product blister formats; it can be configured to process both thermoform and coldform materials, with maximum blister sizes of 220 mm x 155 mm. This versatile line facilitated the integration of a bespoke desiccant feeder that cuts, picks and places reel-fed desiccant wafers into blister pockets.
The off-line Hapa Blister-Jet augments just-in-time production. By printing country-specific artwork and variable data on each individual blister pocket, it enhances flexibility and significantly reduces stock holding.
James MacKenzie, Commercial Director at Hapa notes: “Almac represents an exciting watermark for Hapa. This partnership indicates that our innovation strategy — with high investment in just-in-time, on demand print technologies is on the right track. As order sizes continue to fall, the business case for late stage customisation continues to grow. The addition of the Blister-Jet to Almac’s portfolio extends their capability to provide rapid and efficient late stage customisation of bulk-packed blisters.” He explained that Almac’s partnership-approach to working with clients is shared by Hapa. “Their expertise,”MacKenzie added, “enables us to deliver this project quickly and efficiently.”
David Downey, Almac’s VP of Commercial Operations explains: “This co-investment allows Almac to address complex packaging challenges associated with innovative drug products that require enhanced environmental controls but, importantly, also provides our partners with the option to address modest country-specific market volumes, by off-line printing blank blisters through the Hapa unit. This solution will be of significant value to those companies launching orphan and niche blistered drug products into EU and ROW markets, many of which Almac already support.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance